For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.
Human trial
TUDCA primary study · PMID 25664595
34 ALS patients receiving riluzole in an early proof-of-principle randomized trial.
Reported findings. In the 34-person ALS pilot, 87% with TUDCA versus 43% with placebo met the study-defined responder measure: at least 15% improvement in ALSFRS-R decline slope relative to their own lead-in phase (P=.021). Functional progression was slower; this measure does not mean recovery or a population success rate.
Nonresponse. Not every participant met this slope-based responder definition. The later 336-person phase3 trial did not confirm benefit, reported separately.
Harms. No between-group difference in adverse events was reported in the pilot; small samples cannot establish uncommon or long-term safety.
Limits. A small early disease-specific study is not proof of liver detoxification or a confirmed current ALS treatment. Later trial outcomes must be checked before any treatment conclusion. 2017 corrigendum changes author affiliation only; it does not alter study outcomes. Later phase3 negative findings are recorded separately.
Preparation: Source preparation; commercial equivalence unverified. Route: oral
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human trial
TUDCA-ALS consortium: Phase 3 top-line results (2024)
336 randomized participants with ALS across 25 European sites; consortium announcement March 27, 2024.
Reported findings. No positive effect established on the stated primary outcome.
Nonresponse. The Phase 3 TUDCA-ALS trial did not show significant benefit on its primary functional endpoint or secondary survival and biomarker endpoints.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Top-line consortium report; pandemic recruitment and attrition limited precision. EU-funded research, not a commercial-product equivalence study.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Identity context
Corrigendum.
Publication correction.
Reported findings. The corrigendum changes A. Albanese’s institutional affiliation.
Nonresponse. No outcome, participant-count or statistical correction in this notice.
Harms. Not a clinical safety study.
Limits. Administrative correction must not be represented as evidence that the outcome result was wrong.
Preparation: Publication provenance; not a treatment preparation. Route: not applicable
Read original source ↗Editorial review 2026-10-09. Clinician review pending.